There are 2789 resources available
1213P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in a real-life setting (CLEAR)
Presenter: Rami Nassabein
Session: ePoster Display
1214P - High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20
Presenter: Fenneke Zwierenga
Session: ePoster Display
1215P - EGFR-mutated squamous cell lung cancer and its association with outcomes
Presenter: Yang Xia
Session: ePoster Display
1188P - Concurrent chemoradiotherapy with cisplatin + S-1 for locally advanced non-small cell lung cancer: IPD meta-analysis
Presenter: Yuri Taniguchi
Session: ePoster Display
1189P - EGFR mutation p.747_749del enhances anlotinib sensitivity by upregulating EGR1 and DUSP6 in NSCLC cells
Presenter: yu limeng
Session: ePoster Display
1190TiP - SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab + tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)
Presenter: Rafal Dziadziuszko
Session: ePoster Display
1195P - Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L
Presenter: Sanjay Popat
Session: ePoster Display
1196P - Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1197P - First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN
Presenter: Qing Zhou
Session: ePoster Display
1198P - Anti-ALK autoantibodies in patients with ALK positive non-small cell lung cancer (NSCLC)
Presenter: Claudia Parisi
Session: ePoster Display